GET DAILY SIGNALSProtara Therapeutics (TARA) Q3 2026 Results Highlight Pipeline Momentum
Key Takeaways
- Protara Therapeutics reported a third quarter 2026 net loss of $21.7 million, or $0.35 per share, compared with a net loss of $13.3 million, or $0.31 per share, in the same period last year.
- The $0.35 per-share loss came in slightly narrower than the roughly -$0.36 Wall Street consensus estimate, marking a modest earnings beat.
- Management expects to complete enrollment in the BCG-unresponsive (Bacillus Calmette-Guérin-unresponsive) registrational cohort of the ADVANCED-2 trial for TARA-002 in non-muscle invasive bladder cancer (NMIBC) by the end of 2026.
- The company now expects enrollment in the registrational STARBORN-1 trial to finish in early first quarter 2027 and plans to begin a rolling Biologics License Application (BLA) submission for TARA-002 in lymphatic malformations (LMs).
- For more detail on Protara Therapeutics' major news, today's price move, price targets, and forecasts, visit the dedicated pages.
Earnings Context and Why It Matters
Protara Therapeutics is a clinical-stage biopharmaceutical company, so its quarterly results are measured less by revenue and more by clinical progress and cash runway. The company does not yet generate product sales; instead, investors focus on net loss, research and development (R&D) spending, and milestone execution for its lead asset, TARA-002. With pivotal data and regulatory submissions approaching, this report offers a timely checkpoint on whether the company is on track to transition from a development-stage firm into one with a potential commercial path. A wider loss is expected as trials scale up, but the real question is whether that spending is translating into timely enrollment and regulatory momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter of 2026, Protara reported a net loss of $21.7 million, or $0.35 per share, widening from a net loss of $13.3 million, or $0.31 per share, in the prior-year period. The per-share result was slightly better than the roughly -$0.36 consensus estimate. The company's loss remains driven by R&D investment as it advances TARA-002 across multiple late-stage trials.
Beyond the financials, management provided a pipeline update. The company said it expects to complete enrollment of the BCG-unresponsive registrational cohort of the ADVANCED-2 trial in NMIBC by year-end 2026. Enrollment in the registrational STARBORN-1 trial is now anticipated to complete in early first quarter 2027, and Protara expects to initiate a rolling BLA submission for TARA-002 in lymphatic malformations.
Market Reaction and Investor Sentiment
Shares of Protara Therapeutics closed higher on the day results were released, reflecting a modestly positive reception to a slightly narrower-than-expected loss alongside reaffirmed pipeline milestones. For a pre-revenue biotech, sentiment around earnings tends to hinge less on the bottom line and more on whether clinical timelines remain intact. The confirmation that key trial enrollment is progressing toward completion and that a rolling BLA submission is planned appears to have outweighed the year-over-year widening of the loss. Still, sentiment remains sensitive to any shifts in trial timelines, regulatory updates, or financing needs as the company advances toward potential commercialization.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most important catalysts for Protara are clinical and regulatory rather than financial. Investors should watch whether the company meets its stated enrollment targets for the ADVANCED-2 trial's BCG-unresponsive cohort in NMIBC by the end of 2026, and whether the STARBORN-1 trial finishes enrollment in early 2027 as guided.
Another key item is the rolling BLA submission for TARA-002 in lymphatic malformations. The pace and completeness of that submission will shape how quickly the program can advance toward a potential regulatory decision.
On the financial side, monitoring the company's cash position and cash runway is essential, since Protara funds its operations largely through its balance sheet. Any meaningful delay in clinical timelines or an increase in operating expenses could pressure its runway. Investors will also want to track R&D spending trends as the pivotal trials approach their final stages.
Finally, keep an eye on broader industry dynamics in bladder cancer and rare-disease treatments, where competitive developments and regulatory precedent can influence how the market interprets Protara's progress.
AI Tools in My Research Workflow
In my own analysis, I frequently turn to Tickeron’s AI Screener to quickly filter for clinical-stage biotechs with similar trial timelines and volatility profiles. It helps surface comparable names and technical setups that I might otherwise miss when reviewing a single company’s update. The tool’s customizable filters for fundamentals and AI-driven signals make it a practical addition to the usual earnings review process, especially when evaluating whether a name like Protara Therapeutics stands out relative to peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TARA turns negative, indicating new downward trend
TARA saw its Momentum Indicator move below the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In 77 of the 82 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TARA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for TARA entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TARA's RSI Oscillator exited the oversold zone, 22 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for TARA just turned positive on October 21, 2026. Looking at past instances where TARA's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
Following a +2.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where TARA advanced for three days, in 173 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
TARA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.843) is normal, around the industry mean (3.498). P/E Ratio (-1.691) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. TARA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TARA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage company, which engages in developing treatments for rare and specialty diseases with significant unmet needs.
Industry Biotechnology
Advertisement